RxDoctor Payments Data

Nichole Lemley

Family · Taylorsville, NCNPI 1972270320

Payments from drug & device makers

$735in general payments, 2019–2025

Across 37 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$158
  • Inspire Medical Systems, Inc.$111
  • Novo Nordisk$93
  • AbbVie$59
  • AstraZeneca$56
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$44
  • plus $215 from 11 others

What the payments were for

  • Food & beverage$735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$735 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,654
Medicare patients
72
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$57,251
EliquisApixaban37$43,382
OzempicSemaglutide30$31,812
RybelsusSemaglutide16$15,433
Repatha SureclickEvolocumab13$12,101
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,762
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,952
SymbicortBudesonide/Formoterol Fumarate24$5,650
Omeprazole98$1,693
Albuterol Sulfate HfaAlbuterol Sulfate75$1,477
Atorvastatin Calcium126$1,364
Losartan Potassium109$1,236
Levothyroxine Sodium144$1,207
Fluticasone Propionate71$835
Rosuvastatin Calcium70$823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$158$57,25155 claims
Novo NordiskOzempic, Rybelsus$93$47,24546 claims
PfizerEliquis$21$43,38237 claims
AstraZenecaBreztri Aerosphere, Symbicort$56$13,60236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Taylorsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →